---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013318"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:26:36.304618+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MaxCyte appoints Cynthia Collins to Board; board expands to 10 members

## Summary
- Cynthia Collins appointed as Class II director effective Oct 14, 2024; board expands from 9 to 10.
- Collins to serve on Compensation Committee; receives 97,698 stock options (3-yr vest) and 51,679 RSUs (1-yr vest).
- Over 40 years biotech experience, including CEO of Editas Medicine; boards of Poseida (PSTX), Certara (CERT), and others.
- Disclosure notes past directorship at DermTech (OTC:DMTKQ) which filed Chapter 11 in June 2024; no other regulatory issues.

## SEC filing metadata
- accession: 0001558370-24-013318
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/0001558370-24-013318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/mxct-20241014x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013318
- JSON: https://secwatch.observer/filing/0001558370-24-013318.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.